Cancentus
PrivateLast Round
Accelerator
Apr 14, 2026
Total Funding Raised
$560,000
Company Overview
Cancentus is a biotechnology company that develops selective cancer therapies by exploiting oncogene-induced DNA replication stress, a key vulnerability unique to cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cancentus Comparables
Compare Cancentus with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FoRx Therapeutics | 78% | |
| Artios Pharma | 76% | |
| Rakovina Therapeutics Inc. | 76% | |
Cancentus Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Apr 14, 2026 |
Cancentus Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innosuisse | Accelerator |
| BaseLaunch | Accelerator |
Cancentus Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cancentus's valuation, stock price, and market status.